Frontlight ResearchEarly access
What researchers published on Mantle cell lymphoma
2,638 papers, newest first.
Showing 20 of 219
Trial resultCD19 CAR T-cell therapy (GLPG5101) for relapsed or refractory B-cell non-Hodgkin lymphoma (ATALANTA-1): phase 1 results from a single-arm, multicentre, phase 1/2 study.The Lancet. Haematology
In plain wordsRead moreRead the paper on PubMedTrial resultGlofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.British journal of haematology
In plain wordsRead moreRead the paper on PubMedTrial resultTrials in progress: CARMAN - study protocol of a randomized controlled, international, multicenter, open-label phase II trial evaluating early treatment intensification in patients with high-risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance as compared to standard of care induction and maintenance.BMC cancer
Trial resultA distinct CAR-T cell phenotype mediates therapeutic response at limited doses.Nature communications
In plain wordsRead moreRead the paper on PubMedTrial resultMolecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.Blood advances
In plain wordsRead moreRead the paper on PubMedTrial resultAcalabrutinib in patients with mantle cell lymphoma subjected to allogeneic hematopoietic cell transplantation. a phase 2 study by the Polish Lymphoma Research Group (PLRG12 trial).Annals of hematology
In plain wordsRead moreRead the paper on PubMedRandomised trialFirst-line ibrutinib plus venetoclax for nonblastoid mantle cell lymphoma in patients ≥65 years old or with TP53 mutations.Blood
In plain wordsRead moreRead the paper on PubMedRandomised trialRituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
In plain wordsRead moreRead the paper on PubMedTrial resultPhase I/II Study of Sonrotoclax (BGB-11417) Monotherapy in Patients With Mantle Cell Lymphoma Previously Treated With Anti-CD20 Therapy and a Bruton Tyrosine Kinase Inhibitor.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
In plain wordsRead moreRead the paper on PubMedRandomised trialPsychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.Journal of patient-reported outcomes
In plain wordsRead moreRead the paper on PubMedTrial resultOutcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell Lymphoma.American journal of hematology
In plain wordsRead moreRead the paper on PubMedTrial resultAn Evaluation of Ibrutinib and Ixazomib in Patients With Relapsed/Refractory Mantle Cell Lymphoma: PrE0404.Clinical lymphoma, myeloma & leukemia
In plain wordsRead moreRead the paper on PubMedRandomised trialAddition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.Lancet (London, England)
In plain wordsRead moreRead the paper on PubMedTrial resultMosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.Blood
In plain wordsRead moreRead the paper on PubMedTrial resultPhase 1 Trial of BCL-2 Inhibitor Lisaftoclax (APG-2575) in Chinese Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Other Non-Hodgkin Lymphomas.Clinical lymphoma, myeloma & leukemia
In plain wordsRead moreRead the paper on PubMedTrial resultZanubrutinib-rituximab followed by shortened chemoimmunotherapy as frontline treatment for mantle cell lymphoma (CHESS): a phase II trial.Nature communications
In plain wordsRead moreRead the paper on PubMedTrial resultIbrutinib exposure correlates with improved efficacy of CAR T cells in patients with mantle cell lymphoma.Blood advances
In plain wordsRead moreRead the paper on PubMedTrial resultPatient-reported outcomes among patients with mantle cell lymphoma or chronic lymphocytic leukemia receiving pirtobrutinib in the BRUIN phase 1/2 study: final analysis.Current medical research and opinion
In plain wordsRead moreRead the paper on PubMedTrial resultEfficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).Clinical cancer research : an official journal of the American Association for Cancer Research
In plain wordsRead moreRead the paper on PubMedTrial resultMRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.Blood advances
In plain wordsRead moreRead the paper on PubMed